BIOMAT Database Logo BIOMAT Database Logo

Gemfibrozil in the treatment of dyslipidaemia. A 5-year follow-up study. 1982

V Manninen, and M Mälkönen, and A Eisalo, and J Virtamo, and J Tuomilehto, and P Kuusisto

UI MeSH Term Description Entries
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008079 Lipoproteins, VLDL A class of lipoproteins of very light (0.93-1.006 g/ml) large size (30-80 nm) particles with a core composed mainly of TRIGLYCERIDES and a surface monolayer of PHOSPHOLIPIDS and CHOLESTEROL into which are imbedded the apolipoproteins B, E, and C. VLDL facilitates the transport of endogenously made triglycerides to extrahepatic tissues. As triglycerides and Apo C are removed, VLDL is converted to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LOW-DENSITY LIPOPROTEINS from which cholesterol is delivered to the extrahepatic tissues. Pre-beta-Lipoprotein,Prebeta-Lipoprotein,Prebeta-Lipoproteins,Very Low Density Lipoprotein,Very-Low-Density Lipoprotein,Very-Low-Density Lipoproteins,Lipoprotein VLDL II,Lipoproteins, VLDL I,Lipoproteins, VLDL III,Lipoproteins, VLDL1,Lipoproteins, VLDL2,Lipoproteins, VLDL3,Pre-beta-Lipoproteins,Lipoprotein, Very-Low-Density,Lipoproteins, Very-Low-Density,Pre beta Lipoprotein,Pre beta Lipoproteins,Prebeta Lipoprotein,Prebeta Lipoproteins,VLDL Lipoproteins,VLDL1 Lipoproteins,VLDL2 Lipoproteins,VLDL3 Lipoproteins,Very Low Density Lipoproteins
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010421 Pentanoic Acids Straight-chain CARBOXYLIC ACIDS with the general formula C5H10O2. Acids, Pentanoic
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

V Manninen, and M Mälkönen, and A Eisalo, and J Virtamo, and J Tuomilehto, and P Kuusisto
Treatment of selective mutism: a 5-year follow-up study.
August 2018, European child & adolescent psychiatry,
V Manninen, and M Mälkönen, and A Eisalo, and J Virtamo, and J Tuomilehto, and P Kuusisto
Gemfibrozil in dyslipidaemia.
February 1990, The Journal of the Association of Physicians of India,
V Manninen, and M Mälkönen, and A Eisalo, and J Virtamo, and J Tuomilehto, and P Kuusisto
Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study.
April 2006, Archives of internal medicine,
V Manninen, and M Mälkönen, and A Eisalo, and J Virtamo, and J Tuomilehto, and P Kuusisto
The treatment of parasomnias with hypnosis: a 5-year follow-up study.
June 2007, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine,
V Manninen, and M Mälkönen, and A Eisalo, and J Virtamo, and J Tuomilehto, and P Kuusisto
[Idiopathic club foot--Ponseti treatment--a 5-year follow-up study].
January 2009, Zeitschrift fur Orthopadie und Unfallchirurgie,
V Manninen, and M Mälkönen, and A Eisalo, and J Virtamo, and J Tuomilehto, and P Kuusisto
Bulimia nervosa: a 5-year follow-up study.
November 1992, Psychological medicine,
V Manninen, and M Mälkönen, and A Eisalo, and J Virtamo, and J Tuomilehto, and P Kuusisto
Dinitrochlorbenzene (DNCB) treatment of viral warts. A 5-year follow-up study.
January 1984, Acta dermato-venereologica,
V Manninen, and M Mälkönen, and A Eisalo, and J Virtamo, and J Tuomilehto, and P Kuusisto
Prospective study of alcoholism treatment in Kuwait: a 5-year follow-up report.
January 1989, Drug and alcohol dependence,
V Manninen, and M Mälkönen, and A Eisalo, and J Virtamo, and J Tuomilehto, and P Kuusisto
A 5-year follow-up study of suicide attempts.
March 1996, Acta psychiatrica Scandinavica,
V Manninen, and M Mälkönen, and A Eisalo, and J Virtamo, and J Tuomilehto, and P Kuusisto
Aggressive periodontitis: 5-year follow-up of treatment.
June 2002, Journal of periodontology,
Copied contents to your clipboard!